Circulating Tumor Cells Detected Using EpAb3-5 as Prognostic Indicators in Head and Neck Squamous Cell Carcinoma

Area of Science:

• Oncology
• Immunology
• Biomarkers

Background:

• Epithelial cell adhesion molecule (EpCAM) is a transmembrane protein implicated in cell adhesion and cancer progression.
• Anti-EpCAM antibodies, such as EpAb3-5, are utilized for detecting circulating tumor cells (CTCs).
• The clinical and prognostic significance of EpAb3-5 in head and neck squamous cell carcinoma (HNSCC) requires further elucidation.

Purpose of the Study:

• To evaluate the sensitivity of EpAb3-5 for CTC detection in HNSCC compared to a commercial platform.
• To assess the correlation between EpAb3-5-detected EpCAM expression and clinicopathologic features in HNSCC.
• To determine the prognostic value of EpAb3-5-detected EpCAM expression, alone and in combination with tumor staging, for patient survival.

Main Methods:

• Retrospective analysis of 66 HNSCC patients.
• Enumeration of CTCs using EpAb3-5 and a MACS EpCAM-based platform.
• Immunohistochemical assessment of tumor EpCAM expression using EpAb3-5.
• Kaplan-Meier and Cox regression analyses for survival outcomes.

Main Results:

• EpAb3-5 demonstrated significantly higher CTC detection sensitivity than the MACS platform (p < 0.001).
• Tumor EpCAM expression correlated with nodal status (p < 0.01) but not T classification or overall stage.
• Low EpCAM expression, assessed by EpAb3-5, predicted better overall survival in early-stage HNSCC patients (p < 0.05).

Conclusions:

• EpAb3-5 offers enhanced CTC detection sensitivity and provides prognostic information in HNSCC when integrated with tumor staging.
• EpCAM immunoreactivity assessed by EpAb3-5 may refine risk stratification in early-stage HNSCC.
• Further validation in larger prospective cohorts is warranted to confirm these exploratory findings.